MARKET INSIGHTS
Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody market size was valued at USD 450 million in 2024. The market is projected to grow from USD 495 million in 2025 to USD 1,066 million by 2032, exhibiting a CAGR of 13.4% during the forecast period.
CEACAM5 Antibody is an immune protein specifically targeting the CEACAM5 antigen, clinically recognized as Carcinoembryonic Antigen (CEA). This biomarker shows elevated expression in epithelial cancers, particularly colorectal (occurring in approximately 95% of cases), pancreatic (70-80%), and gastric carcinomas (50-60%). These antibodies serve as critical diagnostic tools through immunohistochemistry and ELISA techniques, with emerging applications in targeted cancer therapies.
The market expansion is driven by rising cancer incidence - the World Health Organization reported 10 million cancer deaths globally in 2020 - coupled with advancements in companion diagnostics. While North America currently dominates with 38% market share due to established healthcare infrastructure, Asia-Pacific shows the fastest growth (projected 15.2% CAGR) because of improving diagnostic capabilities in emerging economies. Recent developments include Thermo Fisher's 2023 launch of CEACAM5 IHC antibodies with improved specificity, reflecting the industry's focus on precision diagnostics.
MARKET DYNAMICS
MARKET DRIVERS
Growing Prevalence of Gastrointestinal and Breast Cancers to Accelerate CEACAM5 Antibody Demand
The rising incidence of cancers associated with CEACAM5 overexpression, particularly colorectal, pancreatic and breast cancers, is driving substantial growth in the CEACAM5 antibody market. With gastrointestinal cancers accounting for approximately 25% of global cancer cases and breast cancer representing 12.5% of all new cancer cases worldwide annually, the diagnostic and research applications of CEACAM5 antibodies are expanding. These antibodies serve as critical tools for immunohistochemistry testing, enabling pathologists to identify and characterize tumors with high specificity. The global increase in cancer screening programs further amplifies the demand for reliable diagnostic biomarkers like CEACAM5.
Advancements in Immunotherapy Development Creating New Clinical Applications
Significant progress in antibody-based cancer therapies is generating new opportunities for CEACAM5 antibodies in therapeutic development. As pharmaceutical companies increasingly investigate CEACAM5 as a potential target for antibody-drug conjugates (ADCs) and bispecific antibodies, the research applications of CEACAM5 antibodies are expanding beyond diagnostics. Several investigational therapies targeting CEACAM5 are currently in clinical trials, including phase II studies for non-small cell lung cancer and pancreatic cancer treatments. This therapeutic potential is driving increased R&D investments, with the global ADC market projected to exceed $10 billion by 2025, creating substantial ancillary demand for high-quality research antibodies.
➤ Leading pharmaceutical companies have reported a nearly 40% increase in CEACAM5-related research publications over the past three years, reflecting growing scientific interest in this biomarker.
Furthermore, technological advancements in antibody production, including recombinant DNA techniques and phage display systems, are enabling manufacturers to develop CEACAM5 antibodies with higher specificity and consistent batch-to-batch reproducibility. These improvements are critical for both diagnostic accuracy and therapeutic development applications.
MARKET RESTRAINTS
High Development Costs and Technical Complexities in Antibody Production
While the CEACAM5 antibody market shows strong growth potential, the specialized nature of antibody development presents significant barriers. Producing research-grade antibodies with high specificity for CEACAM5 requires sophisticated facilities and experienced personnel, with development costs for a new monoclonal antibody often exceeding $200,000. The process involves complex steps including antigen design, immunization strategies, and rigorous validation protocols. These high upfront costs create pricing pressures that may limit accessibility for some research institutions, particularly in developing regions where healthcare budgets are constrained.
Additionally, achieving consistent performance across different detection platforms (flow cytometry, ELISA, IHC) remains challenging. Variations in epitope recognition, antibody affinity, and cross-reactivity can affect experimental results, requiring manufacturers to invest heavily in quality control processes. These technical challenges contribute to longer development timelines and higher product costs that may restrain market expansion.
MARKET CHALLENGES
Regulatory Hurdles and Validation Requirements for Diagnostic Applications
The transition of CEACAM5 antibodies from research tools to clinically validated diagnostic reagents presents substantial regulatory challenges. Obtaining IVD (In Vitro Diagnostic) certification requires rigorous clinical validation across diverse patient populations, with studies demonstrating both analytical and clinical performance. The typical validation process can take 18-24 months and cost millions of dollars, representing a significant barrier for smaller manufacturers. Additionally, regulatory requirements vary substantially across geographic markets, creating compliance complexities for companies pursuing global distribution.
Other Challenges
Competition from Alternative Biomarkers
Emerging alternative cancer biomarkers are creating competitive pressure in the diagnostic space. While CEACAM5 remains important for certain cancer types, newer markers with potentially higher specificity are entering clinical validation, potentially limiting long-term demand.
Sample Stability Issues
Pre-analytical variables in tissue sample preparation can affect CEACAM5 detection reliability. Variations in fixation methods, storage conditions, and antigen retrieval techniques contribute to inter-laboratory variability that challenges standardization efforts.
MARKET OPPORTUNITIES
Expansion into Emerging Markets and Point-of-Care Testing
Significant growth opportunities exist in emerging markets where healthcare infrastructure development and increasing cancer awareness are driving diagnostic market expansion. Countries in Asia-Pacific and Latin America are investing heavily in oncology diagnostic capabilities, with the Asia-Pacific in vitro diagnostics market projected to grow at a CAGR of 8.5% through 2030. Localized production partnerships and strategic pricing models could help CEACAM5 antibody manufacturers capitalize on this growth while overcoming cost barriers in these price-sensitive markets.
The development of rapid, point-of-care CEACAM5 detection systems represents another promising opportunity. Advances in microfluidic technologies and biosensors are enabling the creation of compact testing platforms that could decentralize cancer biomarker testing. Successful development of such systems could expand CEACAM5 testing beyond traditional pathology labs into community healthcare settings. Several companies are currently developing CEACAM5 lateral flow assays and other rapid formats that could revolutionize cancer screening accessibility.
Moreover, increasing academic-industry collaborations are accelerating innovation in CEACAM5 research applications. Recent partnerships between leading antibody suppliers and cancer research centers are yielding novel conjugated antibody formulations optimized for next-generation imaging and therapeutic applications, opening new market segments with premium pricing potential.
Segment Analysis:
By Type
Monoclonal Antibodies Dominate Due to High Specificity in Cancer Diagnostics and Research
The market is segmented based on type into:
-
Monoclonal Antibody
-
Polyclonal Antibody
-
Recombinant Antibody
-
Others
By Application
Flow Cytometry Leads in Market Adoption Due to Growing Demand for Cellular Analysis in Cancer Research
The market is segmented based on application into:
-
Flow Cytometry
-
ELISA
-
Western Blot
-
Immunoprecipitation
-
Immunohistochemistry
-
Others
By End User
Hospitals and Diagnostic Centers Account for Major Usage Due to Rising Cancer Screening Programs
The market is segmented based on end user into:
-
Hospitals and Diagnostic Centers
-
Pharmaceutical and Biotechnology Companies
-
Research and Academic Institutes
-
Contract Research Organizations
COMPETITIVE LANDSCAPE
Key Industry Players
Strategic Innovation Drives Market Leadership in CEACAM5 Antibody Space
The global CEACAM5 antibody market operates in a dynamic semi-consolidated environment, where Thermo Fisher Scientific leads with approximately 18% market share in 2024. Their dominance stems from comprehensive diagnostic solutions for oncology applications and robust distribution networks across 50+ countries. The company's recent acquisition of The Binding Site Group further strengthened its position in specialty diagnostics, including tumor marker detection.
Sino Biological, Inc. and Abcam plc collectively account for nearly 22% of global revenues, according to industry benchmarks. These players differentiate through high-specificity monoclonal antibodies and extensive validation data. Sino Biological's 2024 launch of CEACAM5 antibodies with enhanced sensitivity for pancreatic cancer detection demonstrates the continuous innovation driving competition.
While large-cap firms dominate revenue share, the market sees active participation from specialized manufacturers. Boster Biological Technology and Creative Biolabs have carved niches in cost-effective ELISA kits, capturing emerging market demand. These agile players compete through rapid development cycles - Boster's recent 8-week turnaround for custom CEACAM5 antibodies exemplifies this advantage.
The landscape faces reshaping forces as mid-sized companies pursue strategic collaborations. Bio-Techne and RayBiotech have formed research partnerships with academic centers to develop next-generation diagnostic panels combining CEACAM5 with emerging biomarkers. Such alliances showcase how technical synergy is becoming crucial for market positioning.
List of Key CEACAM5 Antibody Companies Profiled
CEACAM5 ANTIBODY MARKET TRENDS
Increasing Adoption in Cancer Diagnostics Drives Market Growth
The global CEACAM5 antibody market is experiencing robust growth, primarily driven by rising demand in cancer diagnostic applications. CEACAM5 antibodies serve as critical biomarkers for detecting gastrointestinal, pancreatic, and breast cancers, with diagnostic applications growing at approximately 18% annually since 2022. Recent advancements in immunohistochemistry techniques have enhanced the antibody's specificity, enabling earlier detection of malignancies. Furthermore, the integration of CEACAM5 testing in routine cancer screening protocols across developed nations has significantly expanded its clinical utility. Pharmaceutical companies are increasingly incorporating CEACAM5 antibodies into companion diagnostic development, particularly for targeted cancer therapies where biomarker identification is crucial.
Other Trends
Technological Advancements in Antibody Development
Innovations in monoclonal antibody production technologies are revolutionizing the CEACAM5 antibody market. About 65% of newly developed CEACAM5 antibodies now utilize recombinant DNA technology, offering improved consistency and batch-to-batch reproducibility compared to traditional methods. The emergence of humanized antibodies with reduced immunogenicity has expanded therapeutic applications, particularly in radioimmunotherapy and antibody-drug conjugates. Additionally, high-throughput screening platforms have accelerated antibody discovery, reducing development timelines by nearly 40% while enhancing affinity and specificity profiles.
Expanding Applications in Therapeutic Development
The therapeutic potential of CEACAM5 antibodies is gaining significant traction, with over 15 active clinical trials currently evaluating various antibody-based interventions. Antibody-drug conjugates targeting CEACAM5-positive tumors demonstrate promising efficacy, particularly in colorectal cancer, where response rates exceed 45% in phase II trials. Meanwhile, research into bispecific antibodies that simultaneously target CEACAM5 and immune checkpoint markers shows potential for overcoming treatment resistance. The growing pipeline of CEACAM5-targeted therapies is expected to double the market's therapeutics segment by 2028, creating new opportunities for antibody suppliers and contract manufacturers.
Regional Market Diversification
While North America currently dominates with 42% market share, Asia-Pacific is emerging as the fastest-growing region, projected to achieve 17% CAGR through 2030. This growth stems from increasing cancer awareness, improving healthcare infrastructure, and rising investments in precision medicine across China and India. Meanwhile, European markets are advancing through collaborative research initiatives, with over 30 academic-industry partnerships focused on CEACAM5 applications in oncology. Such geographic diversification is reshaping the competitive landscape, prompting global manufacturers to establish localized production and distribution networks.
Regional Analysis: Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market
North America
The North American CEACAM5 antibody market is driven by advanced healthcare infrastructure and significant investments in cancer research, with the U.S. dominating over 85% of the regional market share. Stringent regulatory frameworks, including FDA guidelines for diagnostic antibodies, ensure high-quality product standards, fostering innovation in monoclonal antibody development. The region benefits from strong R&D initiatives in immuno-oncology, particularly for gastrointestinal and breast cancer applications. However, pricing pressures from healthcare payers and lengthy approval processes may hinder market expansion despite the growing demand for precision diagnostics.
Europe
Europe's market growth is underpinned by its robust oncology diagnostic sector and harmonized regulatory environment under EMA oversight. Germany and the UK lead in adoption due to established pathology networks utilizing CEACAM5 antibodies for colorectal cancer screening programs. The region shows increasing preference for validated ELISA and IHC diagnostic kits, though reimbursement limitations for novel antibody-based tests pose challenges. Collaborative projects like Horizon Europe's cancer missions are accelerating translational research, with 22% of European biotech firms actively developing tumor marker antibodies as of 2023.
Asia-Pacific
APAC represents the fastest-growing market, projected to expand at 16.1% CAGR through 2032, fueled by Japan's leadership in monoclonal antibody production and China's burgeoning IVD manufacturing sector. India's increasing cancer burden (1.39 million new cases annually) drives demand for cost-effective CEACAM5 detection kits, while South Korea's advanced healthcare system adopts high-sensitivity western blot applications. Although price sensitivity favors polyclonal antibodies, tier-1 cities demonstrate growing uptake of premium diagnostic solutions. Supply chain constraints and inconsistent regulatory harmonization across ASEAN nations remain key hurdles.
South America
The region shows moderate growth concentrated in Brazil and Argentina, where improving cancer care infrastructure boosts demand for immunohistochemistry antibodies. While economic volatility limits capital-intensive monoclonal antibody adoption, public health initiatives for early cancer detection create opportunities in the flow cytometry segment. Local production remains limited, with 70% of CEACAM5 antibodies imported from North America and Europe. Regulatory delays and currency fluctuations continue to impact market stability, though partnerships with global distributors are improving product accessibility.
Middle East & Africa
Market development is uneven across the region, with UAE, Saudi Arabia and Israel accounting for 68% of CEACAM5 antibody demand through specialized oncology centers. Growing awareness of tumor markers is driving ELISA kit adoption, though diagnostic infrastructure gaps persist in African nations. The lack of local manufacturing forces reliance on imports, creating pricing disparities. While economic diversification initiatives in GCC countries support healthcare investments, political instability in some regions slows market maturation. Strategic collaborations with multinational suppliers aim to address these challenges while meeting rising cancer diagnostic needs.
Report Scope
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Key Coverage Areas:
FREQUENTLY ASKED QUESTIONS:
What is the current market size of Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market?
-> The Global CEACAM5 Antibody market was valued at USD 450 million in 2024 and is expected to reach USD 1066 million by 2032.
Which key companies operate in Global CEACAM5 Antibody Market?
-> Key players include Sino Biological, Inc., Abcam, Thermo Fisher Scientific, Bio-Techne, Merck, and Creative Diagnostics, among others.
What are the key growth drivers?
-> Key growth drivers include rising cancer prevalence, increasing diagnostic applications, and advancements in antibody-based therapies.
Which region dominates the market?
-> North America holds the largest market share, while Asia-Pacific shows the highest growth potential.
What are the emerging trends?
-> Emerging trends include personalized medicine applications, novel therapeutic antibodies, and AI-assisted diagnostic solutions.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Overall Market Size
2.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size: 2024 VS 2032
2.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, Prospects & Forecasts: 2020-2032
2.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales: 2020-2032
3 Company Landscape
3.1 Top Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Players in Global Market
3.2 Top Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Companies Ranked by Revenue
3.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Companies
3.4 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Companies
3.5 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price by Manufacturer (2020-2025)
3.6 Top 3 and Top 5 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Companies in Global Market, by Revenue in 2024
3.7 Global Manufacturers Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Type
3.8 Tier 1, Tier 2, and Tier 3 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Players in Global Market
3.8.1 List of Global Tier 1 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Companies
3.8.2 List of Global Tier 2 and Tier 3 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Companies
4 Sights by Product
4.1 Overview
4.1.1 Segment by Type - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size Markets, 2024 & 2032
4.1.2 Monoclonal Antibody
4.1.3 Polyclonal Antibody
4.2 Segment by Type - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue & Forecasts
4.2.1 Segment by Type - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, 2020-2025
4.2.2 Segment by Type - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, 2026-2032
4.2.3 Segment by Type - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share, 2020-2032
4.3 Segment by Type - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales & Forecasts
4.3.1 Segment by Type - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, 2020-2025
4.3.2 Segment by Type - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, 2026-2032
4.3.3 Segment by Type - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share, 2020-2032
4.4 Segment by Type - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price (Manufacturers Selling Prices), 2020-2032
5 Sights by Application
5.1 Overview
5.1.1 Segment by Application - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, 2024 & 2032
5.1.2 Flow Cytometry
5.1.3 ELISA
5.1.4 Western Blot
5.1.5 Immunoprecipitation
5.1.6 Others
5.2 Segment by Application - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue & Forecasts
5.2.1 Segment by Application - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, 2020-2025
5.2.2 Segment by Application - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, 2026-2032
5.2.3 Segment by Application - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share, 2020-2032
5.3 Segment by Application - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales & Forecasts
5.3.1 Segment by Application - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, 2020-2025
5.3.2 Segment by Application - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, 2026-2032
5.3.3 Segment by Application - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share, 2020-2032
5.4 Segment by Application - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price (Manufacturers Selling Prices), 2020-2032
6 Sights by Region
6.1 By Region - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, 2024 & 2032
6.2 By Region - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue & Forecasts
6.2.1 By Region - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, 2020-2025
6.2.2 By Region - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, 2026-2032
6.2.3 By Region - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share, 2020-2032
6.3 By Region - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales & Forecasts
6.3.1 By Region - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, 2020-2025
6.3.2 By Region - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, 2026-2032
6.3.3 By Region - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share, 2020-2032
6.4 North America
6.4.1 By Country - North America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, 2020-2032
6.4.2 By Country - North America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, 2020-2032
6.4.3 United States Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, 2020-2032
6.4.4 Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, 2020-2032
6.4.5 Mexico Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, 2020-2032
6.5 Europe
6.5.1 By Country - Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, 2020-2032
6.5.2 By Country - Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, 2020-2032
6.5.3 Germany Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, 2020-2032
6.5.4 France Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, 2020-2032
6.5.5 U.K. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, 2020-2032
6.5.6 Italy Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, 2020-2032
6.5.7 Russia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, 2020-2032
6.5.8 Nordic Countries Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, 2020-2032
6.5.9 Benelux Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, 2020-2032
6.6 Asia
6.6.1 By Region - Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, 2020-2032
6.6.2 By Region - Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, 2020-2032
6.6.3 China Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, 2020-2032
6.6.4 Japan Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, 2020-2032
6.6.5 South Korea Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, 2020-2032
6.6.6 Southeast Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, 2020-2032
6.6.7 India Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, 2020-2032
6.7 South America
6.7.1 By Country - South America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, 2020-2032
6.7.2 By Country - South America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, 2020-2032
6.7.3 Brazil Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, 2020-2032
6.7.4 Argentina Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, 2020-2032
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, 2020-2032
6.8.2 By Country - Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, 2020-2032
6.8.3 Turkey Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, 2020-2032
6.8.4 Israel Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, 2020-2032
6.8.5 Saudi Arabia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, 2020-2032
6.8.6 UAE Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size, 2020-2032
7 Manufacturers & Brands Profiles
7.1 Sino Biological, Inc.
7.1.1 Sino Biological, Inc. Company Summary
7.1.2 Sino Biological, Inc. Business Overview
7.1.3 Sino Biological, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Major Product Offerings
7.1.4 Sino Biological, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales and Revenue in Global (2020-2025)
7.1.5 Sino Biological, Inc. Key News & Latest Developments
7.2 LifeSpan BioSciences, Inc
7.2.1 LifeSpan BioSciences, Inc Company Summary
7.2.2 LifeSpan BioSciences, Inc Business Overview
7.2.3 LifeSpan BioSciences, Inc Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Major Product Offerings
7.2.4 LifeSpan BioSciences, Inc Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales and Revenue in Global (2020-2025)
7.2.5 LifeSpan BioSciences, Inc Key News & Latest Developments
7.3 Abcam
7.3.1 Abcam Company Summary
7.3.2 Abcam Business Overview
7.3.3 Abcam Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Major Product Offerings
7.3.4 Abcam Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales and Revenue in Global (2020-2025)
7.3.5 Abcam Key News & Latest Developments
7.4 Thermo Fisher Scientific (China) Co., Ltd.
7.4.1 Thermo Fisher Scientific (China) Co., Ltd. Company Summary
7.4.2 Thermo Fisher Scientific (China) Co., Ltd. Business Overview
7.4.3 Thermo Fisher Scientific (China) Co., Ltd. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Major Product Offerings
7.4.4 Thermo Fisher Scientific (China) Co., Ltd. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales and Revenue in Global (2020-2025)
7.4.5 Thermo Fisher Scientific (China) Co., Ltd. Key News & Latest Developments
7.5 Bio-Techne
7.5.1 Bio-Techne Company Summary
7.5.2 Bio-Techne Business Overview
7.5.3 Bio-Techne Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Major Product Offerings
7.5.4 Bio-Techne Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales and Revenue in Global (2020-2025)
7.5.5 Bio-Techne Key News & Latest Developments
7.6 Boster Biological Technology
7.6.1 Boster Biological Technology Company Summary
7.6.2 Boster Biological Technology Business Overview
7.6.3 Boster Biological Technology Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Major Product Offerings
7.6.4 Boster Biological Technology Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales and Revenue in Global (2020-2025)
7.6.5 Boster Biological Technology Key News & Latest Developments
7.7 Merck
7.7.1 Merck Company Summary
7.7.2 Merck Business Overview
7.7.3 Merck Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Major Product Offerings
7.7.4 Merck Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales and Revenue in Global (2020-2025)
7.7.5 Merck Key News & Latest Developments
7.8 RayBiotech, Inc.
7.8.1 RayBiotech, Inc. Company Summary
7.8.2 RayBiotech, Inc. Business Overview
7.8.3 RayBiotech, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Major Product Offerings
7.8.4 RayBiotech, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales and Revenue in Global (2020-2025)
7.8.5 RayBiotech, Inc. Key News & Latest Developments
7.9 Assay Genie
7.9.1 Assay Genie Company Summary
7.9.2 Assay Genie Business Overview
7.9.3 Assay Genie Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Major Product Offerings
7.9.4 Assay Genie Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales and Revenue in Global (2020-2025)
7.9.5 Assay Genie Key News & Latest Developments
7.10 Creative Biolabs
7.10.1 Creative Biolabs Company Summary
7.10.2 Creative Biolabs Business Overview
7.10.3 Creative Biolabs Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Major Product Offerings
7.10.4 Creative Biolabs Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales and Revenue in Global (2020-2025)
7.10.5 Creative Biolabs Key News & Latest Developments
7.11 MyBiosource, Inc.
7.11.1 MyBiosource, Inc. Company Summary
7.11.2 MyBiosource, Inc. Business Overview
7.11.3 MyBiosource, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Major Product Offerings
7.11.4 MyBiosource, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales and Revenue in Global (2020-2025)
7.11.5 MyBiosource, Inc. Key News & Latest Developments
7.12 OriGene Technologies, Inc.
7.12.1 OriGene Technologies, Inc. Company Summary
7.12.2 OriGene Technologies, Inc. Business Overview
7.12.3 OriGene Technologies, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Major Product Offerings
7.12.4 OriGene Technologies, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales and Revenue in Global (2020-2025)
7.12.5 OriGene Technologies, Inc. Key News & Latest Developments
7.13 Creative Diagnostics
7.13.1 Creative Diagnostics Company Summary
7.13.2 Creative Diagnostics Business Overview
7.13.3 Creative Diagnostics Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Major Product Offerings
7.13.4 Creative Diagnostics Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales and Revenue in Global (2020-2025)
7.13.5 Creative Diagnostics Key News & Latest Developments
7.14 Abbexa
7.14.1 Abbexa Company Summary
7.14.2 Abbexa Business Overview
7.14.3 Abbexa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Major Product Offerings
7.14.4 Abbexa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales and Revenue in Global (2020-2025)
7.14.5 Abbexa Key News & Latest Developments
7.15 Biorbyt
7.15.1 Biorbyt Company Summary
7.15.2 Biorbyt Business Overview
7.15.3 Biorbyt Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Major Product Offerings
7.15.4 Biorbyt Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales and Revenue in Global (2020-2025)
7.15.5 Biorbyt Key News & Latest Developments
7.16 Abeomics Inc.
7.16.1 Abeomics Inc. Company Summary
7.16.2 Abeomics Inc. Business Overview
7.16.3 Abeomics Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Major Product Offerings
7.16.4 Abeomics Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales and Revenue in Global (2020-2025)
7.16.5 Abeomics Inc. Key News & Latest Developments
7.17 CUSABIO
7.17.1 CUSABIO Company Summary
7.17.2 CUSABIO Business Overview
7.17.3 CUSABIO Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Major Product Offerings
7.17.4 CUSABIO Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales and Revenue in Global (2020-2025)
7.17.5 CUSABIO Key News & Latest Developments
7.18 Enzo Life Sciences, Inc.
7.18.1 Enzo Life Sciences, Inc. Company Summary
7.18.2 Enzo Life Sciences, Inc. Business Overview
7.18.3 Enzo Life Sciences, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Major Product Offerings
7.18.4 Enzo Life Sciences, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales and Revenue in Global (2020-2025)
7.18.5 Enzo Life Sciences, Inc. Key News & Latest Developments
8 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Production Capacity, Analysis
8.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Production Capacity, 2020-2032
8.2 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Production Capacity of Key Manufacturers in Global Market
8.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Supply Chain Analysis
10.1 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Industry Value Chain
10.2 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Upstream Market
10.3 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody in Global Market
Table 2. Top Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Players in Global Market, Ranking by Revenue (2024)
Table 3. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Companies, (US$, Mn), 2020-2025
Table 4. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Share by Companies, 2020-2025
Table 5. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Companies, (K Units), 2020-2025
Table 6. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Share by Companies, 2020-2025
Table 7. Key Manufacturers Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price (2020-2025) & (US$/Unit)
Table 8. Global Manufacturers Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Type
Table 9. List of Global Tier 1 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 11. Segment by Type � Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2024 & 2032
Table 12. Segment by Type - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue (US$, Mn), 2020-2025
Table 13. Segment by Type - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue (US$, Mn), 2026-2032
Table 14. Segment by Type - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), 2020-2025
Table 15. Segment by Type - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), 2026-2032
Table 16. Segment by Application � Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2024 & 2032
Table 17. Segment by Application - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2025
Table 18. Segment by Application - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2026-2032
Table 19. Segment by Application - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, (K Units), 2020-2025
Table 20. Segment by Application - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, (K Units), 2026-2032
Table 21. By Region � Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2025-2032
Table 22. By Region - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2025
Table 23. By Region - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2026-2032
Table 24. By Region - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, (K Units), 2020-2025
Table 25. By Region - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, (K Units), 2026-2032
Table 26. By Country - North America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2025
Table 27. By Country - North America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2026-2032
Table 28. By Country - North America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, (K Units), 2020-2025
Table 29. By Country - North America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, (K Units), 2026-2032
Table 30. By Country - Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2025
Table 31. By Country - Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2026-2032
Table 32. By Country - Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, (K Units), 2020-2025
Table 33. By Country - Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, (K Units), 2026-2032
Table 34. By Region - Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2025
Table 35. By Region - Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2026-2032
Table 36. By Region - Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, (K Units), 2020-2025
Table 37. By Region - Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, (K Units), 2026-2032
Table 38. By Country - South America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2025
Table 39. By Country - South America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2026-2032
Table 40. By Country - South America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, (K Units), 2020-2025
Table 41. By Country - South America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, (K Units), 2026-2032
Table 42. By Country - Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2025
Table 43. By Country - Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2026-2032
Table 44. By Country - Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, (K Units), 2020-2025
Table 45. By Country - Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, (K Units), 2026-2032
Table 46. Sino Biological, Inc. Company Summary
Table 47. Sino Biological, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offerings
Table 48. Sino Biological, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 49. Sino Biological, Inc. Key News & Latest Developments
Table 50. LifeSpan BioSciences, Inc Company Summary
Table 51. LifeSpan BioSciences, Inc Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offerings
Table 52. LifeSpan BioSciences, Inc Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 53. LifeSpan BioSciences, Inc Key News & Latest Developments
Table 54. Abcam Company Summary
Table 55. Abcam Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offerings
Table 56. Abcam Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 57. Abcam Key News & Latest Developments
Table 58. Thermo Fisher Scientific (China) Co., Ltd. Company Summary
Table 59. Thermo Fisher Scientific (China) Co., Ltd. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offerings
Table 60. Thermo Fisher Scientific (China) Co., Ltd. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 61. Thermo Fisher Scientific (China) Co., Ltd. Key News & Latest Developments
Table 62. Bio-Techne Company Summary
Table 63. Bio-Techne Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offerings
Table 64. Bio-Techne Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 65. Bio-Techne Key News & Latest Developments
Table 66. Boster Biological Technology Company Summary
Table 67. Boster Biological Technology Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offerings
Table 68. Boster Biological Technology Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 69. Boster Biological Technology Key News & Latest Developments
Table 70. Merck Company Summary
Table 71. Merck Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offerings
Table 72. Merck Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 73. Merck Key News & Latest Developments
Table 74. RayBiotech, Inc. Company Summary
Table 75. RayBiotech, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offerings
Table 76. RayBiotech, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 77. RayBiotech, Inc. Key News & Latest Developments
Table 78. Assay Genie Company Summary
Table 79. Assay Genie Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offerings
Table 80. Assay Genie Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 81. Assay Genie Key News & Latest Developments
Table 82. Creative Biolabs Company Summary
Table 83. Creative Biolabs Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offerings
Table 84. Creative Biolabs Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 85. Creative Biolabs Key News & Latest Developments
Table 86. MyBiosource, Inc. Company Summary
Table 87. MyBiosource, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offerings
Table 88. MyBiosource, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 89. MyBiosource, Inc. Key News & Latest Developments
Table 90. OriGene Technologies, Inc. Company Summary
Table 91. OriGene Technologies, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offerings
Table 92. OriGene Technologies, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 93. OriGene Technologies, Inc. Key News & Latest Developments
Table 94. Creative Diagnostics Company Summary
Table 95. Creative Diagnostics Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offerings
Table 96. Creative Diagnostics Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 97. Creative Diagnostics Key News & Latest Developments
Table 98. Abbexa Company Summary
Table 99. Abbexa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offerings
Table 100. Abbexa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 101. Abbexa Key News & Latest Developments
Table 102. Biorbyt Company Summary
Table 103. Biorbyt Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offerings
Table 104. Biorbyt Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 105. Biorbyt Key News & Latest Developments
Table 106. Abeomics Inc. Company Summary
Table 107. Abeomics Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offerings
Table 108. Abeomics Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 109. Abeomics Inc. Key News & Latest Developments
Table 110. CUSABIO Company Summary
Table 111. CUSABIO Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offerings
Table 112. CUSABIO Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 113. CUSABIO Key News & Latest Developments
Table 114. Enzo Life Sciences, Inc. Company Summary
Table 115. Enzo Life Sciences, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offerings
Table 116. Enzo Life Sciences, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 117. Enzo Life Sciences, Inc. Key News & Latest Developments
Table 118. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Capacity of Key Manufacturers in Global Market, 2023-2025 (K Units)
Table 119. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Capacity Market Share of Key Manufacturers, 2023-2025
Table 120. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Production by Region, 2020-2025 (K Units)
Table 121. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Production by Region, 2026-2032 (K Units)
Table 122. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Opportunities & Trends in Global Market
Table 123. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Drivers in Global Market
Table 124. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Restraints in Global Market
Table 125. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Raw Materials
Table 126. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Raw Materials Suppliers in Global Market
Table 127. Typical Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Downstream
Table 128. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Downstream Clients in Global Market
Table 129. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Picture
Figure 2. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Segment by Type in 2024
Figure 3. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Segment by Application in 2024
Figure 4. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Overview: 2024
Figure 5. Key Caveats
Figure 6. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size: 2024 VS 2032 (US$, Mn)
Figure 7. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue: 2020-2032 (US$, Mn)
Figure 8. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales in Global Market: 2020-2032 (K Units)
Figure 9. The Top 3 and 5 Players Market Share by Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue in 2024
Figure 10. Segment by Type � Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2024 & 2032
Figure 11. Segment by Type - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share, 2020-2032
Figure 12. Segment by Type - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share, 2020-2032
Figure 13. Segment by Type - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price (US$/Unit), 2020-2032
Figure 14. Segment by Application � Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2024 & 2032
Figure 15. Segment by Application - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share, 2020-2032
Figure 16. Segment by Application - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share, 2020-2032
Figure 17. Segment by Application -Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price (US$/Unit), 2020-2032
Figure 18. By Region � Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2025 & 2032
Figure 19. By Region - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share, 2020 VS 2024 VS 2032
Figure 20. By Region - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share, 2020-2032
Figure 21. By Region - Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share, 2020-2032
Figure 22. By Country - North America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share, 2020-2032
Figure 23. By Country - North America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share, 2020-2032
Figure 24. United States Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2032
Figure 25. Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2032
Figure 26. Mexico Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2032
Figure 27. By Country - Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share, 2020-2032
Figure 28. By Country - Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share, 2020-2032
Figure 29. Germany Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2032
Figure 30. France Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2032
Figure 31. U.K. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2032
Figure 32. Italy Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2032
Figure 33. Russia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2032
Figure 34. Nordic Countries Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2032
Figure 35. Benelux Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2032
Figure 36. By Region - Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share, 2020-2032
Figure 37. By Region - Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share, 2020-2032
Figure 38. China Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2032
Figure 39. Japan Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2032
Figure 40. South Korea Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2032
Figure 41. Southeast Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2032
Figure 42. India Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2032
Figure 43. By Country - South America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share, 2020-2032
Figure 44. By Country - South America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Market Share, 2020-2032
Figure 45. Brazil Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2032
Figure 46. Argentina Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2032
Figure 47. By Country - Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, Market Share, 2020-2032
Figure 48. By Country - Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Market Share, 2020-2032
Figure 49. Turkey Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2032
Figure 50. Israel Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2032
Figure 51. Saudi Arabia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2032
Figure 52. UAE Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$, Mn), 2020-2032
Figure 53. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Production Capacity (K Units), 2020-2032
Figure 54. The Percentage of Production Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody by Region, 2024 VS 2032
Figure 55. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Industry Value Chain
Figure 56. Marketing Channels
